Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

Could Smoking Reduce Treatment Effectiveness in Advanced Kidney Cancer?

Could Smoking Reduce Treatment Effectiveness in Advanced Kidney Cancer?

According to a study published in the journal of the American Association of Oncologists, smoking shortens survival in advanced kidney cancer patients receiving sunitinib by reducing treatment effectiveness.

Surgery forms the basis of treatment for kidney cancer, the 8th most common cancer in men and 10th in women, with increasing incidence in recent years. Operations removing all or part of the kidney with surrounding tissues achieve success rates of %70-%100 in early-stage patients. However, surgery cannot cure advanced (metastatic) kidney cancer because the tumor has spread. Resistance to chemotherapy, radiotherapy, and hormonal treatment also makes treatment difficult. Sunitinib, the targeted agent currently used as standard treatment for advanced kidney cancer, can extend survival to 26 months. It works by blocking a group of proteins that cause cancer cells to grow and spread. Sunitinib is an important alternative following immune treatments such as IL-2, which were the only effective treatments used for many years in these patients. Obtaining maximum benefit from it is therefore extremely important.

Smoking is known to contribute to kidney cancer development and progression. By reducing oxygen reaching tissues, it causes reactive oxygen products to form. Their promotion of new blood vessel formation and spread by cancer cells demonstrates smoking's effect on cancer development. A recently published study, however, showed that smoking also affects treatment effectiveness, not only cancer development.

The study grouped 273 patients with metastatic (advanced) kidney cancer receiving sunitinib as never-smokers, current smokers, or former smokers and followed them for approximately 55 months. Time without disease progression (progression-free survival) was 4 months in current smokers versus 12 months in never-smokers; overall survival was 11 months in current smokers versus 25 months in never-smokers. Thus, nonsmoking kidney cancer patients receiving sunitinib had slower cancer progression and significantly longer survival.

In conclusion, this study shows that smoking reduces treatment effectiveness and survival in advanced kidney cancer patients receiving sunitinib. It also suggests similar effects may occur in other cancers, demonstrating how essential it is for cancer patients to quit smoking as soon as possible.

Sources

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

Could Smoking Reduce Treatment Effectiveness in Advanced Kidney Cancer?

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy